vs

Side-by-side financial comparison of GERMAN AMERICAN BANCORP, INC. (GABC) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

GERMAN AMERICAN BANCORP, INC. is the larger business by last-quarter revenue ($126.7M vs $75.5M, roughly 1.7× PUMA BIOTECHNOLOGY, INC.). On growth, GERMAN AMERICAN BANCORP, INC. posted the faster year-over-year revenue change (39.7% vs 27.7%). GERMAN AMERICAN BANCORP, INC. produced more free cash flow last quarter ($154.0M vs $14.4M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 22.7%).

American Express Company or Amex is an American bank holding company and multinational financial services corporation that specializes in payment cards. It is headquartered at 200 Vesey Street, also known as American Express Tower, in the Battery Park City neighborhood of Lower Manhattan.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

GABC vs PBYI — Head-to-Head

Bigger by revenue
GABC
GABC
1.7× larger
GABC
$126.7M
$75.5M
PBYI
Growing faster (revenue YoY)
GABC
GABC
+12.0% gap
GABC
39.7%
27.7%
PBYI
More free cash flow
GABC
GABC
$139.6M more FCF
GABC
$154.0M
$14.4M
PBYI
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
22.7%
GABC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GABC
GABC
PBYI
PBYI
Revenue
$126.7M
$75.5M
Net Profit
$35.7M
Gross Margin
69.3%
Operating Margin
34.6%
22.7%
Net Margin
28.2%
Revenue YoY
39.7%
27.7%
Net Profit YoY
53.7%
EPS (diluted)
$0.98
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GABC
GABC
PBYI
PBYI
Q4 25
$126.7M
$75.5M
Q3 25
$126.5M
$54.5M
Q2 25
$123.2M
$52.4M
Q1 25
$111.1M
$46.0M
Q4 24
$90.7M
$59.1M
Q3 24
$88.5M
$80.5M
Q2 24
$90.5M
$47.1M
Q1 24
$84.1M
$43.8M
Net Profit
GABC
GABC
PBYI
PBYI
Q4 25
$35.7M
Q3 25
$35.1M
$8.8M
Q2 25
$31.4M
$5.9M
Q1 25
$10.5M
$3.0M
Q4 24
$23.2M
Q3 24
$21.0M
$20.3M
Q2 24
$20.5M
$-4.5M
Q1 24
$19.0M
$-4.8M
Gross Margin
GABC
GABC
PBYI
PBYI
Q4 25
69.3%
Q3 25
77.7%
Q2 25
76.5%
Q1 25
77.1%
Q4 24
76.4%
Q3 24
63.9%
Q2 24
77.4%
Q1 24
75.5%
Operating Margin
GABC
GABC
PBYI
PBYI
Q4 25
34.6%
22.7%
Q3 25
34.6%
17.6%
Q2 25
31.8%
12.7%
Q1 25
12.0%
8.7%
Q4 24
31.6%
22.6%
Q3 24
29.0%
27.4%
Q2 24
29.4%
-4.6%
Q1 24
27.6%
-5.3%
Net Margin
GABC
GABC
PBYI
PBYI
Q4 25
28.2%
Q3 25
27.7%
16.2%
Q2 25
25.5%
11.2%
Q1 25
9.5%
6.5%
Q4 24
25.6%
Q3 24
23.8%
25.2%
Q2 24
22.7%
-9.6%
Q1 24
22.6%
-11.0%
EPS (diluted)
GABC
GABC
PBYI
PBYI
Q4 25
$0.98
$0.26
Q3 25
$0.94
$0.17
Q2 25
$0.84
$0.12
Q1 25
$0.30
$0.06
Q4 24
$0.79
$0.40
Q3 24
$0.71
$0.41
Q2 24
$0.69
$-0.09
Q1 24
$0.64
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GABC
GABC
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$97.5M
Total DebtLower is stronger
$100.0M
$22.7M
Stockholders' EquityBook value
$1.2B
$130.3M
Total Assets
$8.4B
$216.3M
Debt / EquityLower = less leverage
0.09×
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GABC
GABC
PBYI
PBYI
Q4 25
$97.5M
Q3 25
$94.4M
Q2 25
$96.0M
Q1 25
$93.2M
Q4 24
$101.0M
Q3 24
$96.7M
Q2 24
$96.8M
Q1 24
$107.2M
Total Debt
GABC
GABC
PBYI
PBYI
Q4 25
$100.0M
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$114.6M
$68.0M
Q3 24
$79.3M
Q2 24
$90.7M
Q1 24
$102.0M
Stockholders' Equity
GABC
GABC
PBYI
PBYI
Q4 25
$1.2B
$130.3M
Q3 25
$1.1B
$115.3M
Q2 25
$1.1B
$104.7M
Q1 25
$1.0B
$97.1M
Q4 24
$715.1M
$92.1M
Q3 24
$744.6M
$71.1M
Q2 24
$687.8M
$48.5M
Q1 24
$655.3M
$51.0M
Total Assets
GABC
GABC
PBYI
PBYI
Q4 25
$8.4B
$216.3M
Q3 25
$8.4B
$202.9M
Q2 25
$8.3B
$194.9M
Q1 25
$8.4B
$196.2M
Q4 24
$6.3B
$213.3M
Q3 24
$6.3B
$220.7M
Q2 24
$6.2B
$205.0M
Q1 24
$6.1B
$214.1M
Debt / Equity
GABC
GABC
PBYI
PBYI
Q4 25
0.09×
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.16×
0.74×
Q3 24
1.12×
Q2 24
1.87×
Q1 24
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GABC
GABC
PBYI
PBYI
Operating Cash FlowLast quarter
$159.3M
$14.4M
Free Cash FlowOCF − Capex
$154.0M
$14.4M
FCF MarginFCF / Revenue
121.6%
19.1%
Capex IntensityCapex / Revenue
4.2%
0.0%
Cash ConversionOCF / Net Profit
4.46×
TTM Free Cash FlowTrailing 4 quarters
$267.0M
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GABC
GABC
PBYI
PBYI
Q4 25
$159.3M
$14.4M
Q3 25
$51.8M
$9.7M
Q2 25
$26.9M
$14.1M
Q1 25
$37.9M
$3.6M
Q4 24
$95.8M
$15.6M
Q3 24
$24.5M
$11.0M
Q2 24
$18.7M
$1.0M
Q1 24
$23.9M
$11.2M
Free Cash Flow
GABC
GABC
PBYI
PBYI
Q4 25
$154.0M
$14.4M
Q3 25
$50.1M
$9.7M
Q2 25
$26.2M
$14.1M
Q1 25
$36.7M
$3.6M
Q4 24
$90.7M
$15.6M
Q3 24
$23.0M
$11.0M
Q2 24
$17.0M
$1.0M
Q1 24
$22.6M
FCF Margin
GABC
GABC
PBYI
PBYI
Q4 25
121.6%
19.1%
Q3 25
39.6%
17.7%
Q2 25
21.2%
26.8%
Q1 25
33.0%
7.7%
Q4 24
100.1%
26.4%
Q3 24
26.0%
13.7%
Q2 24
18.8%
2.1%
Q1 24
26.9%
Capex Intensity
GABC
GABC
PBYI
PBYI
Q4 25
4.2%
0.0%
Q3 25
1.3%
0.0%
Q2 25
0.6%
0.0%
Q1 25
1.1%
0.1%
Q4 24
5.6%
0.0%
Q3 24
1.7%
0.0%
Q2 24
1.8%
0.0%
Q1 24
1.5%
0.0%
Cash Conversion
GABC
GABC
PBYI
PBYI
Q4 25
4.46×
Q3 25
1.48×
1.10×
Q2 25
0.86×
2.41×
Q1 25
3.61×
1.21×
Q4 24
4.13×
Q3 24
1.16×
0.54×
Q2 24
0.91×
Q1 24
1.25×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons